Vanguard Capital Management
BIOA

Vanguard Capital Management’s BioAge Labs BIOA Stock Holding History

Vanguard Capital Management’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.8M Buy
1,544,214
+189,308
+14% +$3.42M ﹤0.01% 2092
2026
Q1 		$23.7M Buy
+1,354,906
New +$26.1M ﹤0.01% 2248

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Vanguard Capital Management's BIOA Position: Q2 2026 in Review

Vanguard Capital Management increased its BioAge Labs (BIOA) stake by 14% in Q2 2026, buying an estimated $3.42M and bringing the position to 1,544,214 shares worth $37.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2092.

Vanguard Capital Management first reported a position in BIOA in Q1 2026 and has held it in 2 quarters since. 151 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • Vanguard Capital Management held 1,544,214 shares of BioAge Labs worth $37.8M as of Q2 2026.
  • Vanguard Capital Management bought 189,308 BioAge Labs shares in Q2 2026, an estimated $3.42M.
  • BioAge Labs made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2092 holding.
  • Vanguard Capital Management first reported a position in BioAge Labs in Q1 2026 and has held it in 2 quarters since.
  • 151 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.